Resources - Volition

VolitionRX Limited: Outlines broad strategy to become the “N…

VolitionRX Limited: Revolutionizing the diagnosis and monito…

The Future of Cancer Diagnostics Webinar with Q&A ̵…

Nu.Q^® Vet Cancer Test Product Brochure (US)

Media & Downloads

Results Interpretation and Post-Test Actions – Nu.Q^® V…

Media & Downloads

How to submit a sample: Video

Subscribe for Volition product updates.

Or, click here for Investor Updates and press releases

"*" indicates required fields

Nu.Q^® Vet Cancer Test Product Deck

Veterinary resources – in clinic (US)

Media & Downloads

Nu.Q^® Vet Cancer Test: How to submit a sample

Media & Downloads

VolitionRx Limited Announces Full Fiscal Year 2024 Financial…

Volition Announces Two Poster Presentations at ESMO’s Europe…

Early detection of stage I/II Lung Cancer by immunoassay of …

Poster & Publications

H3K27Me3-nucleosome is a strong prognostic biomarker in Non-…

Poster & Publications

Volition to Host Virtual Investor Event on Nu.Q^® Cancer, “A …

VolitionRx Announces Pricing of up to $2.3 Million Registere…

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings …

Volition’s Nu.Q^® Cancer Diagnostics Test Aims To Disrupt the…

Volition Introduces Nu.Q^® Cancer Blood Test in New Industry …

Thumbnail lung cancer white paper

Nu.Q^® Cancer White Paper: Lung cancer: hope of a brighter to…

Volition Proudly Sponsors the 44th ISICEM Congress

Volition Signs first ever Nu.Q^® Vet Cancer Test Automation A…

“The NET effect”: Neutrophil extracellular traps—a potential…

Poster & Publications

Chromatin changes associated with neutrophil extracellular t…

Poster & Publications

Volition Announces First Patient Enrolled in NTU Hospital’s …

Accurate Diagnosis of High-Risk Pulmonary Nodules Using a No…

Poster & Publications

Chromatin Changes Associated with Neutrophil Extracellular T…

Poster & Publications

International Women’s Day 2025

Volition’s Nu.Q^® Discover Biomarkers to be utilized in Human…

Volition Showcases Nu.Q^® Vet Cancer Test at the 97th WVC Ann…

Casting a New Light on Sepsis Management – Volition We…

Volition Veterinary at WVC 2025!

Creating an environment where science can thrive: spotlight …

Celebrating Women in Science: Insights from the women workin…

Investor Webinar: Nu.Q^® NETs: Casting a New Light on Sepsis …

Celebrating women in science: empowering the future

Volition Signs First Commercial Project Utilizing Rapid High…

Volition to Host Virtual Investor Event on Nu.Q^® NETs, ̶…

EZH2 inhibition enhances the activity of Carboplatin in aggr…

Poster & Publications

Clinical study establishes Nu.Q^® NETs H3.1 as predictor of 2…

Advancing cancer diagnostics for both ends of the leash

Volition Issues Business Review 2024

Volition Business Review 2024 and a look ahead to 2025, with…

VolitionRx Appoints LifeSci Advisors as Investor Relations C…

Study shows Nu.Q^® Lung Cancer Test differentiated malignant …

VolitionRx Announces Pricing of up to $1.9 Million Registere…

Lung cancer awareness month

VolitionRx Limited Announces Third Quarter 2024 Financial Re…

VolitionRx Limited Schedules Third Quarter 2024 Earnings Con…

Volition Appoints Timothy I. Still as Chairman

The role of canine cancer screening in early cancer detectio…

Multiple studies show Nu.Q^® NETs test could predict sepsis p…

Symposium 2024 report: ‘Sepsis – a brighter hope…

Media & Downloads

Understanding the complex chromatin dynamics in primary huma…

Poster & Publications

Webinar series: How to use Nu.Q^® Vet Cancer Test

Webinar series: What is NETosis?

Webinar series: Clinical Evidence and Upcoming Studies

Webinar series: How Viruses Manipulate Basic Hemostasis to T…

Webinar series: Modeling NETosis in a Clinically Relevant En…

Webinar Series: NETosis Induction in Isolated Neutrophils

Webinar series: Pneumococcus: an example of how bacteria can…

Webinar series: NETs as a Therapeutic Target

Highlights from The European Society of Intensive Care Medic…

Volition to share new ‘NETs in sepsis management’ data insig…

ESICM Symposium: ‘NETs: Casting a new light on sepsis …

About Volition – Our Corporate Video

Nanopore sequencing to elucidate the origins of circulating …

Poster & Publications

NETs: Casting a new light on sepsis management – prese…

Clinical utility of the Nucleosome levels in septic Acute Ki…

Poster & Publications

Volition hosts NETs in sepsis management symposium at ESICM …

Volition Appoints Dr. Ethel Rubin as an Independent Director

Capture-PCR™ video

Capture-PCR™ Product Brochure

Media & Downloads

Nu.Q^® NETs immunoassay detects Neutrophil Extracellular Trap…

Poster & Publications

Prognostic value of circulating nucleosomes during treatment…

Poster & Publications

Volition Hosts KOL Roundtable on Sepsis

Becky’s sepsis story

VolitionRx Limited Announces Second Quarter 2024 Financial R…

VolitionRx Announces Pricing of up to $21.5 Million Register…

How to use the Nu.Q^® H3.1 Test

VolitionRx Limited Schedules Second Quarter 2024 Earnings Co…

Together against canine cancer: an insight into our collabor…

Volition appoints PharmaVentures for Capture PCR™ and oncolo…

Volition’s Non-Hodgkin Lymphoma Research

VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annu…

2024 Mid-Year Review with Cameron Reynolds, Group CEO of Vol…

Physiologically Relevant NETosis Induction Reveals Distinct …

Poster & Publications

Rapid High-Throughput Method for Investigating Physiological…

Poster & Publications

VolitionRx Limited to Present at Jefferies Global Healthcare…

Introducing the Nu.Q^® Vet Cancer Test

How to use the Nu.Q^® Vet Cancer Test

VolitionRx Limited Announces First Quarter 2024 Financial Re…

VolitionRx Limited First Quarter 2024 Financial Results and …

VolitionRx Limited Schedules First Quarter 2024 Earnings Con…

Martin Faulkes retires as Executive Chairman of Volition

Physical isolation of tumour associated ctDNA fragments for …

Poster & Publications

Nu.Q^® Vet Cancer Test launched in-clinic in U.S. and Europe …

Circulating H3K27me3 modified nucleosomes as a biomarker to …

Poster & Publications

Novel ctDNA technology for early cancer detection by immunop…

Poster & Publications

How Nu.Q^® Discover can support drug developers

VolitionRx Limited Announces Full Fiscal Year 2023 Financial…

VolitionRx Limited Full Fiscal Year 2023 Financial Results a…

Utility of Monitoring H3.1 Plasma Concentrations as a Surrog…

Poster & Publications

Baseline values of circulating nucleosomes in Lung Cancer: N…

Poster & Publications

Immunoprecipitation of tumor associated ctDNA fragments for …

Poster & Publications

VolitionRx Limited Schedules Fourth Quarter and Full Year 20…

Volition & Fujifilm Vet Systems Launch Nu.Q^® Vet Cancer…

Volition and Fujifilm Vet Systems Launch Nu.Q^® Vet Cancer Te…

Volition appoints Dr Andrew Retter as Chief Medical Officer

Pet Parents Brochure – The value of canine cancer scre…

Media & Downloads

Highlights from WVC 2024

Nu.Q^® Discover – Markets & Markets Next-Gen Immun…

Novel ctDNA technology for liver cancer detection by immunop…

Poster & Publications

Physical isolation of tumor associated ctDNA fragments for n…

Improve Molecular Residual Disease monitoring by combining c…

Poster & Publications

Nanopore sequencing to reveal the origins of circulating imm…

Identification of an epigenetic profile of circulating nucle…

Poster & Publications

Circulating nucleosomes levels improve FIT performance for d…

Correlation with disease burden and early detection of recur…

Lung nucleosomes containing histone 3.1: a new biomarker for…

Poster & Publications

Nucleosome changes associated with Cancer and NETosis relate…

Poster & Publications

Third Quarter 2023 Financial Results and Business Update

Circulating nucleosomes predict response to tyrosine kinase …

Poster & Publications

Predictive significance of circulating histones in hepatocel…

Poster & Publications

EZH2 inhibition: a promising strategy to prevent cancer immu…

Poster & Publications

Nu.Q® Discover epigenetic profiling for target identification to validation in clinical studies

The epigenetic keys to unlocking the full potential of immun…

Nu.Q^® Discover White Paper: The epigenetic keys to unlocking…

Scientific Advisory Board Update

Meet Ben Berman

Breakthrough Cancer Detection Method Presentation

Media & Downloads

Meet Remi Rabeuf

Genomeweb to Host Volition Webinar on Neutrophils.

Early cancer detection by plasma CTCF transcription factor a…

Webinar – Breakthrough Cancer Detection Method

A novel immunoprecipitation/PCR method for detection of plas…

Poster & Publications

Volition to Share Nu.Q^® NETs Strategy Update at Upcoming Web…

Nu.Q^® NETs: New sepsis study at Guy’s & St Thomas…

Meet Marielle Herzog, our R&D Director

Nu.Q^® Discover Service Product Brochure

Media & Downloads

Nu.Q^® Vet Cancer Test animation

Nu.Q^® Vet Cancer Test Product Brochure (UK & IRL)

Media & Downloads

Focus on Canine Cancer – Media Education Session

Meet Daniel Sheres

Meet Heather Wilson-Robles

Meet Tom Butera

KOL report: Nu.Q^® NETs and sepsis

Media & Downloads

An interview with Professor Heather Wilson-Robles regarding …

Nu.Q^® Cancer Brochure

Media & Downloads

What types of cancer does the Nu.Q^® Vet Cancer Test detect?

What does the Nu.Q^® Vet Cancer Test measure?

When can I expect my results?

When should I be screening my canine patients for cancer?

Hank case study – Nu.Q^® Vet Cancer Test

Otis case study – Nu.Q^® Vet Cancer Test

Belle case study – Nu.Q^® Vet Cancer Test

Nu.Q^® Vet Cancer Test – FAQs

Nu.Q^® Discover H3.1 Kit Product Brochure

Media & Downloads

Volition Issues Business Review 2023

Volition Business Review 2023

High-Throughput Screening to Develop a Biologically Relevan…

Poster & Publications

London Vet Show 2023: Volition Veterinary Highlights.

Nu.Q^® NETs brochure

Media & Downloads

Volition Presents at the 5th Annual Congress of the Internat…

VolitionRx Limited Announces Third Quarter 2023 Financial Re…

VolitionRx Limited Schedules Third Quarter 2023 Earnings Con…

Volition and VPG Launch Nu.Q^® Vet Cancer Test in UK & I…

Breakthrough Cancer Detection Method Webinar – includi…

Differentiation of Malignant and Benign Lung Nodules using E…

Association of Increase of NETosis and Nucleosome Biomarkers…

Poster & Publications

Cell line study of nucleosome-based biomarkers in the diagno…

Poster & Publications

Volition Presents Breakthrough Liquid Biopsy Blood Test Meth…

Measuring Nucleosomes Using Nu.Q^® NETs is a Promising Biomar…

US Ambassador Adler visits Belgian Volition

Association of pronounced elevation of NET formation and nuc…

Poster & Publications

NETs-associated H3.1-nucleosome measurements in plasma corre…

Poster & Publications

Volition Presents Three Cancer Detection Abstracts at ESMO 2…

Liquid biopsies multi-modal analysis correlates with disease…

Poster & Publications

Volition Publishes Key Opinion Leader Roundtable Report on N…

Learn about NETs, NETosis and Nu.Q^® NETs.

Veterinary Cancer Society 2022 Annual Conference

Volition to Reveal New Cancer Detection Method Insights at U…

Epigenetic profiles of elevated cell free circulating H3.1 n…

Poster & Publications

Volition Hosts Key Opinion Leader Roundtable on Sepsis Manag…

Circulating H3K27 Methylated Nucleosome Plasma Concentration

Poster & Publications

VolitionRx Limited Announces Second Quarter 2023 Financial R…

VolitionRx Limited Schedules Second Quarter 2023 Earnings Co…

Volition’s collaboration with Professor Lea Payen and …

VolitionRx Limited Announces Exercise of Over-Allotment Opti…

VolitionRx Limited Announces Closing of $16.5 Million Underw…

Selective cfDNA/NETs apheresis with NucleoCapture

Poster & Publications

VolitionRx Limited Announces Pricing of $16.5 Million Underw…

VolitionRx Limited Announces Proposed Underwritten Public Of…

Plasma H3.1 nucleosome concentrations in dogs with various c…

Scaling Up for Success: Volition Partners with IVD Research …

VolitionRx Secures Approximately $5.5 Million in Belgium Reg…

Volition Study shows Nucleosome Concentrations are a useful …

VolitionRx Limited Announces First Quarter 2023 Financial Re…

Monitoring plasma nucleosome concentrations to measure disea…

Poster & Publications

Removal of circulating nucleosomes/neutrophil extracellular …

Poster & Publications

VolitionRx Limited Schedules First Quarter 2023 Earnings Con…

VolitionRx Limited to Host Capital Markets Day at the NYSE o…

Circulating H3K27 nucleosomes to monitor lung cancer patient…

Poster & Publications

Circulating H3K27 methylated nucleosome concentration in lun…

Poster & Publications

Plasma nucleosome measurement as a biomarker for NETs in int…

Poster & Publications

Understanding NETosis priming and induction through Nucleoso…

Poster & Publications

VolitionRx Limited Announces Full Fiscal Year 2022 Financial…

Genomeweb to Host Volition Webinar on EZH2 Inhibitors.

VolitionRx Limited Schedules Full Year 2022 Earnings Confere…

Highlights from Western Veterinary Conference 2023

VolitionRx Limited Announces Closing of $8.7 Million Underwr…

VolitionRx Limited Announces Pricing of $7.525 Million Under…

VolitionRx Limited Announces Proposed Underwritten Public Of…

Volition’s Nu.Q^® Vet Cancer Test Now Available for Pre…

Celebrating International Day of Women and Girls in Science.

Highlights from Veterinary Meeting & Expo 2023

Meet Gaetan Michel

Volition to Take Part in Nu.Q^® Vet Commercial Strategy Webin…

Volition Announces Expansion of Availability of the Nu.Q^® Ve…

Volition Issues Business Review 2022

Volition Business Review 2022

Highlights from London Vet Show 2022

Our Scientific Advisory Board meeting 2022

Nu.Q ^® Capture-Mass spectrometry – novel proteomics a…

Poster & Publications

A persistent neutrophil-associated immune signature characte…

Poster & Publications

VolitionRx Limited Announces Third Quarter 2022 Financial Re…

Volition Announces Clinical Research Study with Oncovet

Volition to Participate in a Lung Cancer Screening Study in …

VolitionRx Limited Schedules Third Quarter 2022 Earnings Con…

Volition Announces the Launch of the Nu.Q^® Vet Cancer Screen…

Volition Signs Global Supply Agreement for Nu.Q^® Vet Cancer …

Circulating nucleosomes are markers of NETosis and correlate…

Poster & Publications

Detection and evaluation associated with NETosis in human pl…

Poster & Publications

A spotlight on Volition’s Asia Strategy.

A spotlight on…Volition’s Commercialisation Stra…

Interview with Dr Jerome Benoit, Oncovet

Evaluation of plasma nucleosome concentrations in dogs

Poster & Publications

A spotlight on… Volition’s U.S. Clinical Product…

Volition Appoints Mickie Henshall as an Independent Director

VolitionRx Limited Announces Second Quarter 2022 Financial R…

Volition Announces U.S. Clinical Study for NETs

VolitionRx Limited Schedules Second Quarter 2022 Earnings Co…

Volition Appoints DXOCRO to Spearhead U.S. FDA Strategy

VolitionRx Awarded $1.5 Million in Non-Dilutive Funding

VolitionRx Limited Announces Closing of $6.9 Million Underwr…

VolitionRx Limited Announces Pricing of $6 Million Underwrit…

NETosis and nucleosome biomarkers in septic shock

Poster & Publications

Evaluation and comparison of NETosis biomarkers in sepsis an…

Poster & Publications

New NETs Data Presented at International Society on Thrombos…

What is NETosis?

Evaluation of Plasma Nucleosome Concentrations – ACVIM…

Volition to Host Second Genomeweb Webinar.

Volition appoints Sharon Ballesteros as U.S. Head of Quality…

Volition Achieves CE Mark for Nu.Q^® NETs Test

Utility of Serial Plasma Nucleosomes Concentrations for Moni…

Volition Opens New Innovation Hub.

VolitionRx Limited Announces First Quarter 2022 Financial Re…

VolitionRx Limited to Host Capital Markets Day on Friday May…

Epigenetic cancer tests for both ends of the leash.

Volition launches its Nu.Q^®Vet Cancer Test in Asia through i…

Nu.Q ^® Capture-MS allows the epigenetic profile analysis of …

Poster & Publications

Volition presents at EuroMedLab 2022

VolitionRx Limited Announces Full Fiscal Year 2021 Financial…

Volition Signs Exclusive $28 million License and Supply Agre…

VolitionRx Limited Schedules Full Fiscal Year 2021 Earnings …

Highlights from WVC Annual Conference 2022

Meet Tom Butera

Volition Hosts Genomeweb Webinar

Differential Biological Effects of Dietary Lipids and Irradi…

Poster & Publications

Meet Terry Kelly

Circulating Nucleosomes for Detection of Colorectal Cancer …

Circulating nucleosomes for Detection of Colorectal Cancer a…

Poster & Publications

Volition presents study data at ASCO GI 2022 on circulating …

Circulating nucleosomes levels improve FIT performance for d…

Poster & Publications

Business Review 2021

Therapeutic removal of NETs from blood in a pig model of sep…

Poster & Publications

Therapeutic Removal of Neutrophil Extracellular Traps from …

Therapeutic Removal of Neutrophil Extracellular Traps from …

A look to the future of cancer diagnosis

Poster & Publications

Enrichment tools to better understand the types of circulati…

Poster & Publications

Evaluation of plasma nucleosome concentrations as a tool for…

Poster & Publications

Characterizing Circulating Nucleosomes in the Plasma of Dogs…

Poster & Publications

Identifying tools to track hypercoagulability in COVID-19 pa…

Poster & Publications

Characterizing circulating nucleosomes in the plasma of dogs…

Poster & Publications

Circulating Nucleosome Immunoassay: Evaluating a Clinically-…

Poster & Publications

Serial profiling of cell‑free DNA and nucleosome histone mod…

Poster & Publications

A novel proteomics approach to epigenetic profiling of circu…

Poster & Publications

Circulating Nucleosomes as Potential Markers to Monitor COVI…

Poster & Publications

Circulating nucleosomes in lung cancer diagnosis following l…

Volition’s Nu.Q Vet Assay Detects Two Common Canine Cancers

Volition Veterinary – Key Opinion Leader Roundtable

Volition welcomes you to the Veterinary Cancer Society Confe…

Enrichment of circulating tumor DNA from cell-free DNA of he…

Poster & Publications

Circulating nucleosomes in hematological malignancy

Poster & Publications

Performance of a Nu.Q™ H3.1 assay for lung cancer detection

Poster & Publications